A Not-So-Good Way to Die? Respiratory Syncytial Virus–induced Necroptotic Cell Death Promotes Inflammation and Type 2–mediated Pathology

James A Harker,Robert J. Snelgrove,James A. Harker
DOI: https://doi.org/10.1164/rccm.202003-0533ED
IF: 24.7
2020-05-30
American Journal of Respiratory and Critical Care Medicine
Abstract:Respiratory syncytial virus (RSV) is a significant cause of acute respiratory infection in infants, and most children have been infected at least once before the age of 2 years ( 1 ). A small percentage of these children develop viral bronchiolitis and pneumonia associated with intense inflammation in their lower airways. Accordingly, RSV is one of the most significant causes of infant hospitalization in the developed world and a significant cause of infant mortality in the developing world. RSV-dependent lower respiratory tract infections in early life are also associated with an increased prevalence of wheeze and asthma in later life. Despite over 60 years of research into RSV, there is currently no licensed vaccine. In addition, although prophylactic administration of a monoclonal antibody against the RSV F protein can successfully prevent RSV bronchiolitis, its administration after infection has limited benefit. What drives severe disease during RSV-dependent lower respiratory tract infections and which pathways might be therapeutically targeted after infection therefore remain significant questions.
respiratory system,critical care medicine
What problem does this paper attempt to address?